|
See related Actemra infusion conc information |
|
|
|
Manufacturer |
Roche |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Tocilizumab |
|
Indications |
In combination w/ methotrexate (MTX), treatment of moderate to severe active RA in adult patients who have inadequately responded or intolerant to previous therapy w/ DMARDs or tumour necrosis factor (TNF) antagonists; reduction of progression of joint damage & improve physical function. Monotherapy in case of MTX intolerance or where inappropriate.
Click to view Actemra detailed prescribing infomation |
|
Dosage |
8 mg/kg body wt once every 4 wk as IV infusion over 1 hr.
Click to view Actemra detailed prescribing infomation |
|
Overdosage |
View Actemra overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity.
Click to view Actemra detailed prescribing infomation |
|
Special Precautions |
History of recurring/chronic infection, intestinal ulceration/diverticulitis. Patients must be screened for latent TB infection prior to therapy. Hepatic disease or impairment. Monitor ALT & AST levels, neutrophil & platelet count. Perform lipid parameter assessment 4-8 wk following initiation of therapy. Pregnancy & lactation. Childn <18 yr.
Click to view Actemra detailed prescribing infomation |
|
Adverse Drug Reactions |
Upper resp tract infections, cellulitis, oral herpes simplex, Herpes zoster, abdominal pain, mouth ulcer, gastritis, rash, pruritus, urticaria, headache, dizziness, increased wt, increased hepatic transaminases, HTN, leucopenia, neutropenia, hypercholesterolaemia, peripheral oedema, cough, dyspnoea, conjunctivitis.
View ADR Monitoring Form |
|
Drug Interactions |
CYP450 enzymes, simvastatin, atorvastatin, Ca-channel blockers, theophylline, warfarin, phenytoin, ciclosporin, benzodiazepines.
View more drug interactions with Actemra |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Actemra detailed prescribing infomation |
|
Storage |
View Actemra storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Actemra description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Actemra mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
